TW202246317A - 針對呼吸道融合病毒及其他副黏液病毒的抗體以及使用其之方法 - Google Patents

針對呼吸道融合病毒及其他副黏液病毒的抗體以及使用其之方法 Download PDF

Info

Publication number
TW202246317A
TW202246317A TW111104605A TW111104605A TW202246317A TW 202246317 A TW202246317 A TW 202246317A TW 111104605 A TW111104605 A TW 111104605A TW 111104605 A TW111104605 A TW 111104605A TW 202246317 A TW202246317 A TW 202246317A
Authority
TW
Taiwan
Prior art keywords
ser
antibody
val
leu
thr
Prior art date
Application number
TW111104605A
Other languages
English (en)
Chinese (zh)
Inventor
戴維德 寇提
Original Assignee
瑞士商休曼生物醫藥股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商休曼生物醫藥股份公司 filed Critical 瑞士商休曼生物醫藥股份公司
Publication of TW202246317A publication Critical patent/TW202246317A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW111104605A 2021-02-09 2022-02-08 針對呼吸道融合病毒及其他副黏液病毒的抗體以及使用其之方法 TW202246317A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163147676P 2021-02-09 2021-02-09
US63/147,676 2021-02-09

Publications (1)

Publication Number Publication Date
TW202246317A true TW202246317A (zh) 2022-12-01

Family

ID=80461207

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111104605A TW202246317A (zh) 2021-02-09 2022-02-08 針對呼吸道融合病毒及其他副黏液病毒的抗體以及使用其之方法

Country Status (8)

Country Link
US (1) US20240101648A1 (https=)
EP (1) EP4291575A1 (https=)
JP (1) JP2024506321A (https=)
CN (1) CN117136197A (https=)
BR (1) BR112023015900A2 (https=)
CA (1) CA3210502A1 (https=)
TW (1) TW202246317A (https=)
WO (1) WO2022173745A1 (https=)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
EP2471813B1 (en) * 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
CN104350069B (zh) * 2012-03-20 2017-12-01 胡默波斯生物医学公司 中和rsv、mpv和pvm的抗体和其应用
EP3294774B1 (en) 2015-05-13 2024-08-28 Zumutor Biologics, Inc. Afucosylated protein, cell expressing said protein and associated methods
JO3555B1 (ar) * 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
US11479600B2 (en) * 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
WO2019024979A1 (en) * 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
CN117924477A (zh) * 2017-12-19 2024-04-26 洛克菲勒大学 具有改进的效应子功能的人IgG Fc结构域变体
US20220298230A1 (en) * 2019-06-11 2022-09-22 The Rockefeller University Antibodies and methods for treatment of viral infections

Also Published As

Publication number Publication date
CN117136197A (zh) 2023-11-28
WO2022173745A1 (en) 2022-08-18
US20240101648A1 (en) 2024-03-28
BR112023015900A2 (pt) 2023-10-17
CA3210502A1 (en) 2022-08-18
JP2024506321A (ja) 2024-02-13
EP4291575A1 (en) 2023-12-20

Similar Documents

Publication Publication Date Title
TWI859420B (zh) 抗sars-cov-2抗體及使用其之方法
WO2021158521A1 (en) Antibodies against sars-cov-2 and methods of using the same
WO2022204202A1 (en) Antibodies that bind to multiple sarbecoviruses
US20250263467A1 (en) Antibody therapies for sars-cov-2 infection
US20240141021A1 (en) Anti-influenza antibodies and combinations thereof
US20240092876A1 (en) Broadly neutralizing antibodies against influenza neuraminidase
CA3194162A1 (en) Antibodies against sars-cov-2
TWI901812B (zh) 針對a型流感病毒的抗體
TW202417477A (zh) 與多種嚴重急性呼吸道症候群β型冠狀病毒結合之抗體
US20240400652A1 (en) Antibody therapies for sars-cov-2 infection in pediatric subjects
TW202246317A (zh) 針對呼吸道融合病毒及其他副黏液病毒的抗體以及使用其之方法
TW202411247A (zh) 針對流感神經胺酸酶的廣泛中和抗體
WO2023230448A1 (en) Combination immunotherapy for influenza
JP2025526405A (ja) Ｒｓｖ及びｍｐｖパラミクソウイルスに対する広域中和抗体
JP2023553888A (ja) Ａ型インフルエンザ感染の治療のための抗体及び方法
WO2022159842A1 (en) Antibody combination therapies for sars-cov-2 infection
TW202411246A (zh) 經工程化之b型肝炎病毒中和抗體及其用途
WO2023039442A9 (en) Broadly neutralizing antibody combination therapies for sars-cov-2 infection
WO2024118998A2 (en) Engineered anti-sars-cov-2 antibodies and methods of using the same
WO2024086566A2 (en) Pan-sarbecovirus neutralizing antibodies and methods of use thereof
CN116997567A (zh) 抗流感抗体和其组合
WO2023034871A1 (en) High concentration antibody therapies for sars-cov-2 infection